NCT00163202
- Conditions
- Arterial Occlusive Diseases, Arteriosclerosis, Cardiovascular Diseases, +12 more
- Locations
-
- Pfizer Investigational Site Calgary, Alberta, Canada
- Pfizer Investigational Site Edmonton, Alberta, Canada
- Pfizer Investigational Site Vancouver, British Columbia, Canada
- Pfizer Investigational Site Winnipeg, Manitoba, Canada